Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2024 | 2 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
N Engl J Med. 2019.
PMID: 30516102
Clinical Trial.
CONCLUSIONS: Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone. (Funded by F. Hof …
CONCLUSIONS: Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy …
Recommendations for optimising pilot and feasibility work in surgery.
Fairhurst K, Potter S, Blazeby JM, Avery KNL.
Fairhurst K, et al.
Pilot Feasibility Stud. 2024 Apr 18;10(1):64. doi: 10.1186/s40814-024-01489-1.
Pilot Feasibility Stud. 2024.
PMID: 38637818
Free PMC article.
Item in Clipboard
Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT project.
Potter S, Avery K, Ahmed R, de Boniface J, Chatterjee S, Dodwell D, Dubsky P, Iwata H, Jiang M, Lee HB, MacKenzie M, Poulakaki F, Richardson AL, Sepulveda K, Spillane A, Thompson AM, Werutsky G, Wright JL, Zdenkowski N, Cowan K, McIntosh S.
Potter S, et al.
BMJ Open. 2024 Apr 19;14(4):e084488. doi: 10.1136/bmjopen-2024-084488.
BMJ Open. 2024.
PMID: 38643011
Free PMC article.
Item in Clipboard
Cite
Cite